Announcement of New CFO Appointment

GEXVal Inc.
September 25, 2024

GEXVal Inc. (President and CEO: Juran Kato, PhD, Location: Fujisawa, Kanagawa, Japan) is pleased to announce the appointment of Mr. Keiichi Kiyota as our new Chief Financial Officer (CFO).

This strategic appointment aims to strengthen our management structure and accelerate our company’s growth and value creation. Mr. Kiyota brings a wealth of experience and expertise to GEXVal, including an outstanding career as a MR at a leading global pharmaceutical company, entrepreneurial experience in founding a biotech company, providing invaluable insights into global business operations, exceptional track record in finance, accounting, and management within the biotech sector.

Notably, Mr. Kiyota successfully led a biotech company to an IPO in Japan during the challenging economic climate following the 2008 financial crisis. This achievement showcases his ability to navigate complex financial landscapes, which will be a crucial asset for GEXVal’s growth strategy and financial management.  

Since 2022, Mr. Kiyota has served as an executive advisor to GEXVal, demonstrating a deep alignment with our purpose and business model. His strong support and understanding of our company are expected to be significant drivers in our future endeavors.

Juran Kato, PhD, President and CEO of GEXVal, commented: "We are thrilled to welcome Mr. Kiyota to our executive team. His extensive experience and keen insights will elevate our financial strategy and significantly contribute to building a sustainable growth platform. With this enhanced management structure, we are poised for further advancement and are committed to delivering our best performance. We will endeavor to excel in all aspects of our business for patients and families."

Mr. Kiyota shared his enthusiasm: "I am honored to join GEXVal and contribute to the development and execution of innovative corporate strategies that will  enhance our company’s value. I am committed to deliver innovative medicines to patients and families who live with diseases with high unmet medical needs. I look forward to maximizing GEXVal’s potential and creating substantial value for our patients and their families, shareholders, and all stakeholders."

With this new addition to our leadership team, GEXVal is set to pursue further growth and value creation with renewed vigor.

For further information:
Head of Corporate office
Atsushi Sugizaki
info@gexval.com